|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
12,653,000 |
Market
Cap: |
2.37(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$0.187 - $0.187 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Kiora Pharmaceuticals is a clinical-stage pharmaceutical company focused on developing products for treating disorders of the eye. Co.'s key product in clinical development is the EyeGate Ocular Bandage Gel, a topically applied eye drop formulation of modified hyaluronic acid (HA). HA is a naturally occurring polymer that is used in various physiological processes, including wound healing, hydration, tissue homeostasis, and joint lubrication. Co. modifies the HA through chemical cross-linking, which allows it to adhere to the ocular surface providing protection and lubrication for the treatment of corneal wounds, defects, and epitheliopathies.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
0 |
0 |
0 |
0 |
Total Sell Value |
$0 |
$0 |
$0 |
$0 |
Total People Sold |
0 |
0 |
0 |
0 |
Total Sell Transactions |
0 |
0 |
0 |
0 |
End Date |
2024-03-07 |
2023-12-05 |
2023-06-06 |
2022-06-06 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Chaney Paul G |
Director |
|
2018-07-10 |
4 |
A |
$0.00 |
$0 |
D/D |
50,000 |
91,229 |
|
- |
|
Tyle Praveen |
Director |
|
2018-07-10 |
4 |
A |
$0.00 |
$0 |
D/D |
50,000 |
61,893 |
|
- |
|
Garanzini Michael |
Chief Commercial Officer |
|
2018-07-10 |
4 |
A |
$0.00 |
$0 |
D/D |
25,000 |
196,250 |
|
- |
|
Wirostko Barbara |
Chief Medical Officer |
|
2018-07-10 |
4 |
A |
$0.00 |
$0 |
D/D |
175,000 |
424,997 |
|
- |
|
Malfroy-Camine Bernard |
Director |
|
2018-07-10 |
4 |
A |
$0.00 |
$0 |
D/D |
50,000 |
61,525 |
|
- |
|
Mann Brenda |
VP of Research & Development |
|
2018-07-10 |
4 |
A |
$0.00 |
$0 |
D/D |
175,000 |
193,473 |
|
- |
|
Goldberg Morton |
Director |
|
2018-07-10 |
4 |
A |
$0.00 |
$0 |
D/D |
50,000 |
59,441 |
|
- |
|
Romano Sarah |
Chief Financial Officer |
|
2018-07-10 |
4 |
A |
$0.00 |
$0 |
D/D |
175,000 |
281,863 |
|
- |
|
Manzo Michael P. |
VP of Engineering |
|
2018-07-10 |
4 |
A |
$0.00 |
$0 |
D/D |
175,000 |
194,546 |
|
- |
|
Wirostko Barbara |
Chief Medical Officer |
|
2018-06-08 |
4/A |
A |
$0.54 |
$3,780 |
I/I |
7,000 |
59,915 |
|
- |
|
Wirostko Barbara |
Chief Medical Officer |
|
2018-06-08 |
4 |
A |
$0.54 |
$3,780 |
D/D |
7,000 |
249,612 |
|
- |
|
Wirostko Barbara |
Chief Medical Officer |
|
2018-06-07 |
4/A |
A |
$0.52 |
$4,992 |
D/D |
9,600 |
249,997 |
|
- |
|
Wirostko Barbara |
Chief Medical Officer |
|
2018-06-07 |
4/A |
A |
$0.52 |
$1,152 |
I/I |
2,215 |
52,915 |
|
- |
|
Wirostko Barbara |
Chief Medical Officer |
|
2018-06-07 |
4 |
A |
$0.52 |
$1,152 |
D/D |
2,215 |
242,612 |
|
- |
|
Boyd Steven |
Director |
|
2018-05-29 |
4 |
B |
$0.00 |
$0 |
I/I |
0 |
16,802,500 |
2.17 |
- |
|
Boyd Steven |
Director |
|
2018-05-29 |
4 |
B |
$0.57 |
$23,317 |
D/D |
40,700 |
16,802,500 |
3.92 |
- |
|
Boyd Steven |
Director |
|
2018-05-25 |
4 |
B |
$0.00 |
$0 |
I/I |
0 |
16,761,800 |
2.17 |
- |
|
Boyd Steven |
Director |
|
2018-05-25 |
4 |
B |
$0.58 |
$10,116 |
D/D |
17,575 |
16,761,800 |
3.92 |
- |
|
Boyd Steven |
Director |
|
2018-05-18 |
4 |
B |
$0.00 |
$0 |
I/I |
0 |
16,744,225 |
2.17 |
- |
|
Boyd Steven |
Director |
|
2018-05-18 |
4 |
B |
$0.56 |
$959 |
D/D |
1,725 |
16,744,225 |
3.84 |
- |
|
Boyd Steven |
Director |
|
2018-05-14 |
4 |
B |
$0.00 |
$0 |
I/I |
0 |
16,742,500 |
2.17 |
- |
|
Boyd Steven |
Director |
|
2018-05-14 |
4 |
B |
$0.53 |
$8,417 |
D/D |
15,758 |
16,742,500 |
3.84 |
- |
|
Boyd Steven |
10% Owner |
|
2018-05-11 |
4 |
B |
$0.00 |
$0 |
I/I |
0 |
16,726,742 |
1.42 |
- |
|
Boyd Steven |
10% Owner |
|
2018-05-11 |
4 |
B |
$0.54 |
$26,438 |
D/D |
49,142 |
16,726,742 |
2.37 |
- |
|
Boyd Steven |
10% Owner |
|
2018-05-10 |
4 |
B |
$0.00 |
$0 |
I/I |
0 |
16,677,600 |
1.42 |
- |
|
289 Records found
|
|
Page 8 of 12 |
|
|